Barchas Amends Immunome Stake Filing

TL;DR

Barchas updated his Immunome 13D filing, effective Jan 1, 2024.

AI Summary

Isaac Barchas filed an amendment (No. 1) to his Schedule 13D on August 21, 2024, regarding his beneficial ownership of Immunome Inc. common stock. The filing indicates a change in the date of the event requiring the filing to January 1, 2024. Barchas is listed with an address in Dallas, TX, and the filing concerns Immunome Inc., a pharmaceutical preparations company incorporated in Delaware.

Why It Matters

This amendment updates the reporting of beneficial ownership for Immunome Inc., potentially signaling changes in investor strategy or holdings that could influence the stock's trading.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant investor activity, which can lead to increased stock volatility.

Key Players & Entities

• Isaac Barchas (person) — Filing person and beneficial owner
• Immunome Inc. (company) — Subject company
• 20240821 (date) — Filing date
• January 1, 2024 (date) — Date of event requiring filing

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• immunome13d.htm (SC 13D/A) — 556KB
• 0001123292-24-000228.txt ( ) — 557KB

Identity and Background

Item 2. Identity and Background.

of the Schedule 13D is hereby amended and restated to read as follows

Item 2 of the Schedule 13D is hereby amended and restated to read as follows: (a) This Statement is being filed by: 1. Arsenal Bridge Venture II, LLC, a Delaware limited liability company ("ABV II"), 2. Arsenal Bridge Venture II-B, LLC, a Delaware limited liability company ("ABV II-B"), 3. Arsenal Bridge Advisors, LLC, a Delaware limited liability company (the "Investment Adviser") 4. RBP Catalyst Fund, L.P., a Delaware limited partnership ("RBP Catalyst"), 5. Research Bridge Partners, Inc., a Delaware corporation ("RBP"), 6. Isaac Barchas, and 7. James Graham (collectively, the "Reporting Persons"). Each of ABV II, ABV II-B, RBP Catalyst, RBP and Isaac Barchas is the record and direct beneficial owner of the shares of Common Stock covered by this Statement. The Investment Adviser is the investment adviser of ABV II and ABV II-B and may be deemed to beneficially own securities owned by ABV II and ABV II-B pursuant to a power of attorney from ABHMC II, LLC, the managing member of ABV II and ABV II-B. Each of Isaac Barchas and James Graham may be deemed to beneficially own securities owned by ABV II and ABV II-B. RBP is the general partner of RBP Catalyst and may be deemed to beneficially own securities owned by RBP Catalyst. Mr. Barchas was previously the Chief Executive Officer of RBP and exercised voting and investment power over the shares owned by RBP and RBP Catalyst, and therefore may have been deemed to beneficially own securities owned RBP and RBP Catalyst. On January 1, 2024, Mr. Barchas resigned as Chief Executive Officer of RBP and no longer exercises voting and investment power over the shares owned by RBP and RBP Catalyst. RBP and RBP Catalyst are no longer members of the Schedule 13(d) group and shall cease to be Reporting Persons immediately upon filing of this Amendment No. 1. (b) The address of the principal business office of each Reporting Person is 1807 W. 11th Street, Austin, Texas, 78703. (c) The principal business of ABV II

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration.

of the Schedule 13D is hereby amended and supplemented by adding the following

Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following: On October 27, 2023, Mr. Barchas received a grant of 41,538 unvested stock options of Immunome under Immunome's non-employee director compensation policy, of which 13,846 stock options are exercisable within 60 days of August 21, 2024.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. (a) and (b) The information set forth in Items 7-13 of the cover pages is hereby incorporated by reference into this

(a) and (b)

Item 5(a) and (b). (c) The information set forth in Item 3 is hereby incorporated by reference into this Item 5(c). Except as set forth in this Statement, none of the Reporting Persons or, to the best knowledge of the Reporting Persons, any of the other persons set forth on Schedule 1, has effected any transactions in the Common Stock in the past 60 days. (d) Not applicable. (e) The Reporting Persons ceased to be the beneficial owner of more than five percent of the Common Stock on February 16, 2024. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct. Dates: August 21, 2024 Arsenal Bridge Venture II, LLC By: ABHMC II, LLC, its Managing Member By: /s/ Isaac Barchas Name: Isaac Barchas Title: Managing Member Arsenal Bridge Venture II-B, LLC By: ABHMC II, LLC, its Managing Member By: /s/ Isaac Barchas Name: Isaac Barchas Title: Managing Member Arsenal Bridge Advisors, LLC By: /s/ Isaac Barchas Name: Isaac Barchas Title: Authorized Person RBP Catalyst Fund, L.P. By: Research Bridge Partners, LLC, its General Partner By: /s/ Isaac Barchas Name: Isaac Barchas Title: Managing Member Research Bridge Partners, Inc. By: /s/ Isaac Barchas Name: Isaac Barchas Title: President & CEO /s/ Isaac Barchas Isaac Barchas /s/ James Graham James Graham SCHEDULE 1 Executive Officers and Directors The name and principal occupation of each executive officer and director of Research Bridge Partners, Inc. ("RBP") are set forth below. The address for each person listed below is c/o Research Bridge Partners, Inc., 1807 W. 11th Street, Austin, Texas, 78703. All executive officers and directors listed are United States citizens. Except as included in the Schedule 13D, none of the executive officers or directors of RBP owns any shares of common stock, par value $0.0001 per share, of Immunome, Inc. Executive Officer: N

View Full Filing

View this SC 13D/A filing on SEC EDGAR